Novo Holdings to acquire Catalent in $16.5B deal
Summary
At that time, Catalent will become a private company, and its shares will no longer trade on the New York Stock Exchange. “Over the past several years, Catalent has built a comprehensive end-to-end offering of services and capabilities to drive innovation in the health care system and improve patient outcomes. This transaction is a testament to our team’s hard work and dedication to this mission, and I am incredibly excited for this next step in our journey,” Catalent President and CEO Alessandro Maselli said in a statement. With our expertise and track record of investing in high quality life sciences businesses, we believe Catalent is a very good strategic fit. We are excited to support the Company’s stakeholders in the years ahead, especially employees and customers as they work to develop new products to benefit patients.” Additionally, Novo Holdings intends to sell Catalent’s fill-finish sites in Anagni, Italy; Bloomington, Ind., and Brussels, Belgium.